All articles tagged: Chronic leukemia of unspecified cell type not having achieved remission (C95.10)
HealthDay
21 December at 04.47 PM
American Society of Hematology, Dec. 9 to 12The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and |
|
HealthDay
19 December at 04.47 PM
Robust Score Can ID Infection Risk in Newly Diagnosed Multiple MyelomaA robust score can identify patients with newly diagnosed multiple myeloma (NDMM) at risk for severe infection/death, according to a study published online Dec. 7 in Leukemia.Elias K. Mai, M.D., from the University Hospital Heidelberg in Germany, and colleagues examined 3,700 transplant-eligible NDMM patients treated in 2005 to 2020 wi |
|
HealthDay
19 December at 04.59 AM
Air Pollution May Increase Risk for Childhood LeukemiaExposure to traffic-related air pollution may be associated with an increased risk for childhood leukemia, according to a study published in the August issue of Environment International.Christian Kreis, Ph.D., from the University of Bern in Switzerland, and colleagues investigated the association between traffic-related air pollution |
|
HealthDay
13 December at 03.59 PM
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in LeukemiaFor patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held f |
|
HealthDay
13 December at 03.33 PM
Increasing Body Mass Index Tied to 18 Site-Specific Cancers in MenIncreasing body mass index (BMI) at age 18 years is associated with development of subsequent site-specific cancers in men, according to a study published online Nov. 6 in Obesity.Aron Onerup, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues examined BMI at age 18 years and incident site-specific cancer ( |
Evalytics
05 December at 05.25 PM
FDA investigating risk of secondary cancers after CAR-T therapy to treat cancerThe FDA is investigating the risk of secondary cancers in patients treated with CAR-T therapies, used for certain cancers like leukemia and lymphoma. Nineteen cases of T-cell malignancies have been reported following these treatments. While CAR-T therapies are beneficial, there's growing concern about their potential risks, including serious T-cell malignancies. The FDA advises lifelong monitoring |
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
|
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
|
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
|
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
|
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
|
|
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
|
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |
|
Medpage Today
13 June at 06.56 PM
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60% of melanoma patients who do not benefit or develop resistance to the drugs... |
|
Medpage Today
08 June at 04.00 PM
Here Are the Top Supreme Court Health Cases to WatchBy early July, the Supreme Court will release its most controversial rulings for the 2023-2024 term. The Court's 6-3 conservative supermajority has already overturned Roe v. Wade, sharply limited affirmative action, expanded... |
Newsletter for Healtcare
Join over 1.2M subscribers and receive one weekly email.
